摘要
目的 探讨经肝动脉化疗栓塞治疗（TACE）对原发性肝癌患者细胞免疫功能的影响.方法 对89例原发性肝癌患者行TACE治疗,TACE所用药物为：阿霉素40～60 mg,5-氟尿嘧啶1 000～1 250 mg,奥沙利铂150～200 mg,亚叶酸钙300mg,碘化油平均用量10 mL.分别于治疗前及治疗后4周取外周血2 mL,以流式细胞仪检测T淋巴细胞亚群CD3^＋、CD4^＋、CD8^＋细胞百分数及CD4^＋/CD8^＋比值,并与30例健康人相对照.结果 与健康对照组比较,原发性肝癌患者CD3^＋、CD4^＋及CD4^＋/CD8^＋比值明显降低（P＜0.05）,分别为（33.2±17.5）％、（14.2±7.1）％和0.87±0.53.TACE治疗4周后CD3^＋、CD4^＋均高于治疗前,CD8＋较治疗前下降,但差异无统计学意义（P＞0.05）,而CD4^＋/CD8^＋比值升至1.98±0.72,明显高于治疗前（P＜0.05）.结论 原发性肝癌患者细胞免疫功能低下,TACE治疗可促进患者的T淋巴细胞免疫功能恢复.
Objective To explore the effect of transcatheter arterial chemoembolization （TACE） on the cellular immunity function in the patients with primary hepatic cancer（PHC）. Methods Eighty-nine cases of P HC were treated by TACE. The drugs of TACE were adriamycin 40-60 mg, 5-Fu 1 000-1 250 mg,oxaliplatin 150-200 mg and leucovorin 300rag respectively. The average dosage of iodinated oil was 10 mL. 2 mL of peripheral blood was collected before treatment and at 4 weeks after treatment. The values of T cell subsets （CD3^＋ ,CD4^＋ ,CD8^＋ and CD4^＋/CD8^＋） were determined by using flow cytometry and controlled with those of 30 healthy persons. Results Compared with the healthy control group,the percentages of CD3^＋ ,CD4^＋ and the ratio of CD4^＋/CD8^＋ in the patients with primary hepatic cancer were decreased significantly, which were （33.2±17.5）%, （14.2 ±7.1）% and 0.87 ±0.53 respectively. At 4 weeks after TACE treatment, the percentages of CD3^＋ ,CD4^＋ were higher than before treatment and the level of CD8^＋ was decreased compared with before treatment （P〉0.05） ,while the ratio of CD4^＋/CD8^＋ was increased to 1.98±0.72,which was significantly higher than that before treatment（P〈0.05）. Conclusion The cellular immunity function in the patients with PHC is decreased,and the T cell immunity function will be improved after TACE treatment.
出处
《重庆医学》
CAS
北大核心
2016年第31期4382-4384,共3页
Chongqing medicine
基金
中央高校基本科研业务经费综合交叉类科研项目(XJJ2014148)
关键词
肝肿瘤
T淋巴细胞亚群
细胞免疫
化疗栓塞
介入治疗
live neoplasms
T cell subsets
cellular immunity function
transcatheter arterial chemoembolization
interventiontherapy
